The survey, published July 10, tested for coronavirus antibodies in the blood of about 5,000 people across the city from March 15-31. The results showed 44.5% of those tested had antibodies, indicating they had been infected with Covid-19.
Jakarta has a population of about 10.6 million, government figures show. According to the researchers, as many as 4.7 million people may have been infected in the capital by March 31.
“Through this survey, we can estimate the proportion of Jakarta residents who have been infected by the SARS CoV-2 virus, whether identified by PCR tests or not,” said Widyastuti, head of Jakarta’s Provincial Health Office, in an online press conference on July 10, state-run news agency Antara reported.
Dr. Pandu Riono, an epidemiologist from the University of Indonesia’s school of public health, said the survey found some people are at higher risk than others, Antara reported.
“People in densely populated areas are more susceptible to being infected with Covid-19,” he said. “The higher the body mass index, the more infected, in this case [those who are] overweight and obese. People with high blood sugar levels are also more at risk.”

vCard.red is a free platform for creating a mobile-friendly digital business cards. You can easily create a vCard and generate a QR code for it, allowing others to scan and save your contact details instantly.
The platform allows you to display contact information, social media links, services, and products all in one shareable link. Optional features include appointment scheduling, WhatsApp-based storefronts, media galleries, and custom design options.
The report also found the highest number of antibodies in the 30-49 age group and that infection rates were higher in women.
Focus on vaccinations
Scientists have found it’s likely that people recovering from coronavirus have some immunity — but it’s not clear how strong it is or how long it lasts.
“In an open city like Jakarta — which has high intra- and inter-region mobility — it is hard to achieve herd immunity,” the researchers said.
“We have agreed that the Moderna vaccine will be given as a third dose to provide maximum immunity to the existing viral mutations,” he said.